share_log

Canaccord Genuity Initiates Coverage On Passage Bio With Buy Rating, Announces Price Target of $8

Benzinga Real-time News ·  Nov 8, 2022 18:01

Canaccord Genuity analyst Whitney Ijem initiates coverage on Passage Bio (NASDAQ:PASG) with a Buy rating and announces Price Target of $8.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment